Conyers advises Hony Capital Fund V and New Good Management on privatisation of Simcere
Conyers Dill & Pearman has advised Hony Capital Fund V and New Good Management on the $495m (£300m) privatisation of Simcere Pharmaceutical Group from the New York Stock Exchange (NYSE) by way of merger.
Simcere is a pharmaceutical company specialising in the development, manufacture and marketing of branded and proprietary pharmaceuticals in China.
Conyers co-chair David Lamb and associate Angie Chu, both based in Conyers’ Hong Kong office, acted in this matter. They worked alongside Cleary Gottlieb Steen & Hamilton and Shearman & Sterling.
News from Conyers Dill & Pearman
Briefings from Conyers Dill & Pearman
You may be flying your personal or private jet in the US or through Europe, but registration in such jurisdictions may not be the right decision for you.
The Offshore Case Digest summarises the major commercial cases decided in Bermuda, the British Virgin Islands and Cayman between March and June 2014.